CJC-1295 (with DAC), also referred to in the literature as DAC:GRF, is a synthetic analogue of growth hormone-releasing hormone built on the truncated GRF(1-29) sequence and conjugated to a Drug Affinity Complex. AminoOptimization Group supplies it as a lyophilised research powder in a 5 mg presentation, tested to 99% purity by HPLC, with a Certificate of Analysis available for the lot supplied. This material is offered strictly for laboratory research use. It is not a drug, and it is not for human or veterinary use.
What is CJC-1295 (with DAC)?
The backbone of this molecule is the same 29-amino-acid fragment of endogenous growth hormone-releasing hormone used in Modified GRF(1-29) work, carrying the four substitutions described in published sequence-activity studies as reducing susceptibility to enzymatic cleavage, in particular by dipeptidyl peptidase-4 at the N-terminus. On its own, that backbone is cleared from circulation quickly.
The Drug Affinity Complex changes that. DAC is a maleimidopropionic acid group attached to the peptide chain that reacts with the free thiol of cysteine-34 on serum albumin, forming a covalent bond between the two molecules. Because albumin itself has a long circulating half-life, literature on DAC-conjugated peptides describes the bound analogue as persisting in circulation for a substantially longer period than the unconjugated GRF fragment — a pharmacokinetic property, not a claim about any outcome.
This distinction is what separates the two CJC-1295 variants in study design. Where the No-DAC form produces a short, discrete pulse of receptor agonism, the DAC-conjugated form is examined in models of sustained, near-continuous receptor occupancy. Researchers select between the two depending on whether the variable under investigation is a transient or a prolonged signal at the GHRH receptor.
Specifications
- Compound: CJC-1295 (with DAC) / DAC:GRF(1-29)
- CAS number: 446262-90-4
- Molecular formula: C165H269N47O46
- Molecular weight: 3647.25 g/mol
- Purity: 99% HPLC
- Presentation: Lyophilised powder, sealed vial
- Available sizes: 5 mg
- Physical form: White to off-white powder
- Classification: Research peptide — not for human or veterinary use
Research context
Published research on DAC-conjugated GHRH analogues focuses on the consequences of prolonged receptor agonism at the anterior pituitary, in contrast to work on unconjugated GRF fragments that examines pulsatile stimulation. The albumin-binding mechanism itself is a subject of study: how covalent conjugation at cysteine-34 alters the compound’s distribution and clearance relative to the free peptide, and how that altered pharmacokinetic profile is reflected in downstream signalling in model systems.
Because sustained agonism differs mechanistically from the pulsatile pattern associated with endogenous GHRH release, this compound appears in comparative study designs alongside Modified GRF(1-29) and growth hormone secretagogue receptor ligands, where researchers examine how signal duration and pattern — rather than presence alone — shape observed responses at the receptor and cellular level.
None of this literature establishes safety or efficacy for use in humans. It is provided as research context only.
Reconstitution
Lyophilised peptide must be reconstituted with a suitable sterile diluent before it can be used in solution. Bacteriostatic water, which contains a preservative permitting repeated withdrawals, is the diluent most often specified for multi-use laboratory preparations; sterile water is more typical where the material will be used once.
Direct the diluent stream against the interior wall of the vial rather than onto the powder, and let the material dissolve on its own. Peptides are sensitive to shear stress, so do not shake the vial — swirl it gently if dissolution is slow, and expect the powder to go fully into solution within a few minutes at room temperature.
The concentration of the resulting solution depends on how much diluent is added to a given vial mass. Our peptide reconstitution calculator computes the resulting concentration for any combination of vial size and diluent volume.
Storage and stability
Before reconstitution: keep the sealed vial frozen at -20 °C, protected from light. Lyophilised peptide is relatively stable in this state, and brief excursions to ambient temperature during shipping are normal and not expected to compromise a properly lyophilised product.
After reconstitution: refrigerate at 2–8 °C and keep the solution away from light. Peptide in solution is considerably less stable than the lyophilised powder. Repeated freeze-thaw cycling is a documented cause of aggregation and should be avoided; if a protocol requires repeated sampling over time, aliquot the reconstituted material instead.
Examine solutions before use. Cloudiness, particulate matter, or discolouration indicate the material should not be relied on for quantitative work.
Certificate of Analysis
Each lot is tested by high-performance liquid chromatography, and the purity figure listed above reflects analytical results for the specific lot supplied rather than a generic specification. A Certificate of Analysis is available on request, and lot-specific documentation can be provided before purchase where a protocol requires it.
Purity by HPLC is a statement about the proportion of target peptide relative to detectable related substances in the material as manufactured and tested. It is expressly not a representation of fitness for any use in humans or animals.
Handling and safety
Handle this material in accordance with good laboratory practice. Use appropriate personal protective equipment, work within a suitable containment environment, and dispose of material and consumables according to your institution’s requirements and applicable local regulation. Anyone handling this material should understand that it is not for human or veterinary use.
Frequently asked questions
What is the difference between CJC-1295 with DAC and CJC-1295 without DAC?
The Drug Affinity Complex forms a covalent bond with serum albumin, which substantially extends the compound’s circulating profile relative to the unconjugated GRF(1-29) fragment. Researchers select between the two forms depending on whether their study design calls for sustained or pulsatile receptor agonism.
Is CJC-1295 with DAC approved in Canada?
No. This compound has not been evaluated or authorised by Health Canada, the FDA, or any comparable regulatory authority. It carries no DIN or NPN, its safety and efficacy for human use have not been assessed, and it is supplied for laboratory research only.
How much diluent should be used to reconstitute CJC-1295 with DAC?
That depends on the working concentration a given protocol requires. Use the peptide reconstitution calculator to compute the resulting concentration for your vial size and diluent volume.
How long does CJC-1295 with DAC remain stable once reconstituted?
Stability in solution is shorter than in lyophilised form and depends on diluent, temperature, and handling. Refrigerate at 2–8 °C, protect from light, avoid freeze-thaw cycling, and validate stability under your own storage conditions if your work depends on it.
Do you provide a Certificate of Analysis for CJC-1295 with DAC?
Yes — lot-specific, available on request, including before purchase.
Research use only
This product is supplied solely for laboratory and scientific research. It is not a drug, food, cosmetic, or medical device, and it must not be administered to humans or animals. Nothing on this page is medical advice or a therapeutic claim. Full terms are set out in our Research Use Only Disclaimer.
Reviews
There are no reviews yet.